Prolonged androgen receptor loading onto chromatin and the efficient recruitment of p160 coactivators contribute to androgen-independent growth of prostate cancer cells
- PMID: 18780293
- DOI: 10.1002/pros.20849
Prolonged androgen receptor loading onto chromatin and the efficient recruitment of p160 coactivators contribute to androgen-independent growth of prostate cancer cells
Abstract
Background: Growth of most ablation-resistant prostate cancers (CaPs) is dependent on androgen receptor (AR) activity in chromatin, but cancer cells in these tumors have acquired altered AR activation. It is unclear how the aberrantly activated AR loads onto regulatory regions of AR-targeted genes. The purpose of this study was to assess the AR chromatin loading in an androgen-depleted environment.
Methods: The expression of PSA in androgen-resistant CaP cells was determined using RT-PCR and Western blot analysis. In order to investigate the binding of the AR to the PSA gene regulatory regions, chromatin immunoprecipitation (ChIP) was performed in the androgen-independent cds2 cell line in the presence or absence of androgens. In addition, we examined the involvement of p160 coactivators in the chromatin loading of the AR.
Results: It was found that constitutive activation of PSA expression was the result of sustained occupancy by the AR at the regulatory region of this gene. This stable AR loading was not blocked by the AR antagonist bicalutamide. Furthermore, androgen-resistant CaP cells highly expressed both AR and the p160 coactivators and the AR was able to recruit TIF2. Downregulation of TIF2 using short hairpin RNA disrupted the AR loading to the PSA enhancer and subsequently inhibited AR activity.
Conclusion: Prolonged AR localization to the regulatory regions of AR targeted genes and the recruitment of p160 coactivators are a potential mechanism leading to androgen-independent activation of the AR. Disruption of AR chromatin loading could therefore become an important therapeutic target for this disease.
Similar articles
-
Activity of androgen receptor antagonist bicalutamide in prostate cancer cells is independent of NCoR and SMRT corepressors.Cancer Res. 2007 Sep 1;67(17):8388-95. doi: 10.1158/0008-5472.CAN-07-0617. Cancer Res. 2007. PMID: 17804755
-
Coregulator recruitment and histone modifications in transcriptional regulation by the androgen receptor.Mol Endocrinol. 2004 Nov;18(11):2633-48. doi: 10.1210/me.2004-0245. Epub 2004 Aug 12. Mol Endocrinol. 2004. PMID: 15308689
-
Metformin represses androgen-dependent and androgen-independent prostate cancers by targeting androgen receptor.Prostate. 2015 Aug 1;75(11):1187-96. doi: 10.1002/pros.23000. Epub 2015 Apr 20. Prostate. 2015. PMID: 25894097
-
Expression and function of androgen receptor coactivators in prostate cancer.J Steroid Biochem Mol Biol. 2004 Nov;92(4):265-71. doi: 10.1016/j.jsbmb.2004.10.003. Epub 2004 Dec 19. J Steroid Biochem Mol Biol. 2004. PMID: 15663989 Review.
-
Androgen Receptor Coactivators in Regulation of Growth and Differentiation in Prostate Cancer.J Cell Physiol. 2016 Feb;231(2):270-4. doi: 10.1002/jcp.25099. J Cell Physiol. 2016. PMID: 26201947 Review.
Cited by
-
Cyclin D1 is a selective modifier of androgen-dependent signaling and androgen receptor function.J Biol Chem. 2011 Mar 11;286(10):8117-8127. doi: 10.1074/jbc.M110.170720. Epub 2011 Jan 5. J Biol Chem. 2011. PMID: 21212260 Free PMC article.
-
Reciprocal feedback inhibition of the androgen receptor and PI3K as a novel therapy for castrate-sensitive and -resistant prostate cancer.Oncotarget. 2015 Dec 8;6(39):41976-87. doi: 10.18632/oncotarget.5659. Oncotarget. 2015. PMID: 26506516 Free PMC article.
-
High Content Positional Biosensor Assay to Screen for Compounds that Prevent or Disrupt Androgen Receptor and Transcription Intermediary Factor 2 Protein-Protein Interactions.Methods Mol Biol. 2018;1683:211-227. doi: 10.1007/978-1-4939-7357-6_13. Methods Mol Biol. 2018. PMID: 29082495 Free PMC article.
-
Peroxisome proliferator-activated receptor gamma coactivator-1alpha interacts with the androgen receptor (AR) and promotes prostate cancer cell growth by activating the AR.Mol Endocrinol. 2010 Jan;24(1):114-27. doi: 10.1210/me.2009-0302. Epub 2009 Nov 2. Mol Endocrinol. 2010. PMID: 19884383 Free PMC article.
-
Assays to Interrogate the Ability of Compounds to Inhibit the AF-2 or AF-1 Transactivation Domains of the Androgen Receptor.Assay Drug Dev Technol. 2019 Nov/Dec;17(8):364-386. doi: 10.1089/adt.2019.940. Epub 2019 Sep 6. Assay Drug Dev Technol. 2019. PMID: 31502857 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous